Sagimet Biosciences (SGMT) Competitors

$7.37 -0.23 (-3.03%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$7.22 -0.15 (-1.97%)

As of 08:12 AM Eastern

SGMT vs. PHAT, MRVI, ORIC, SDGR, and XNCR

Should you buy Sagimet Biosciences stock or one of its competitors? MarketBeat compares Sagimet Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sagimet Biosciences include Phathom Pharmaceuticals (PHAT), Maravai LifeSciences (MRVI), Oric Pharmaceuticals (ORIC), Schrodinger (SDGR), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Sagimet Biosciences (NASDAQ:SGMT) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Sagimet Biosciences had 8 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for Sagimet Biosciences and 3 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.07 beat Sagimet Biosciences' score of 0.59 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences currently has a consensus target price of $28.63, suggesting a potential upside of 288.40%. Phathom Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 91.57%. Given Sagimet Biosciences' higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Sagimet Biosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sagimet Biosciences has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	120.06	-$51.04M	-$1.34	N/A
Phathom Pharmaceuticals	$175.11M	5.94	-$221.25M	-$2.12	N/A

Sagimet Biosciences has a beta of 3.6, meaning that its share price is 260% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Summary

Sagimet Biosciences beats Phathom Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Sagimet Biosciences compare to Maravai LifeSciences?

Sagimet Biosciences (NASDAQ:SGMT) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Maravai LifeSciences had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 12 mentions for Maravai LifeSciences and 11 mentions for Sagimet Biosciences. Maravai LifeSciences' average media sentiment score of 0.64 beat Sagimet Biosciences' score of 0.59 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Sagimet Biosciences has a beta of 3.6, meaning that its share price is 260% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Sagimet Biosciences has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Sagimet Biosciences currently has a consensus target price of $28.63, suggesting a potential upside of 288.40%. Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential upside of 28.21%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Maravai LifeSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sagimet Biosciences has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	120.06	-$51.04M	-$1.34	N/A
Maravai LifeSciences	$185.74M	5.94	-$130.77M	-$0.71	N/A

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sagimet Biosciences beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

In the previous week, Sagimet Biosciences had 7 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 11 mentions for Sagimet Biosciences and 4 mentions for Oric Pharmaceuticals. Sagimet Biosciences' average media sentiment score of 0.59 beat Oric Pharmaceuticals' score of 0.58 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Sagimet Biosciences	$2M	120.06	-$51.04M	-$1.34	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oric Pharmaceuticals' return on equity of -35.33% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Oric Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.6, meaning that its share price is 260% more volatile than the broader market.

Oric Pharmaceuticals presently has a consensus target price of $19.80, indicating a potential upside of 137.41%. Sagimet Biosciences has a consensus target price of $28.63, indicating a potential upside of 288.40%. Given Sagimet Biosciences' higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Sagimet Biosciences beats Oric Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Sagimet Biosciences compare to Schrodinger?

Sagimet Biosciences (NASDAQ:SGMT) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Sagimet Biosciences has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Schrodinger	-40.61%	-30.85%	-15.32%

Sagimet Biosciences has a beta of 3.6, meaning that its share price is 260% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sagimet Biosciences has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	120.06	-$51.04M	-$1.34	N/A
Schrodinger	$255.87M	3.64	-$103.26M	-$1.41	N/A

Sagimet Biosciences currently has a consensus price target of $28.63, indicating a potential upside of 288.40%. Schrodinger has a consensus price target of $20.25, indicating a potential upside of 60.46%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Sagimet Biosciences had 4 more articles in the media than Schrodinger. MarketBeat recorded 11 mentions for Sagimet Biosciences and 7 mentions for Schrodinger. Sagimet Biosciences' average media sentiment score of 0.59 beat Schrodinger's score of 0.53 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sagimet Biosciences beats Schrodinger on 13 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Xencor?

Sagimet Biosciences (NASDAQ:SGMT) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Sagimet Biosciences had 2 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Sagimet Biosciences and 9 mentions for Xencor. Sagimet Biosciences' average media sentiment score of 0.59 beat Xencor's score of 0.53 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences currently has a consensus price target of $28.63, indicating a potential upside of 288.40%. Xencor has a consensus price target of $24.50, indicating a potential upside of 106.23%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Sagimet Biosciences has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Xencor	-177.10%	-28.77%	-20.52%

Sagimet Biosciences has a beta of 3.6, meaning that its share price is 260% more volatile than the broader market. Comparatively, Xencor has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Sagimet Biosciences has higher earnings, but lower revenue than Xencor. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	120.06	-$51.04M	-$1.34	N/A
Xencor	$125.58M	7.01	-$91.92M	-$2.29	N/A

87.9% of Sagimet Biosciences shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 4.8% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sagimet Biosciences beats Xencor on 12 of the 16 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$247.65M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-5.50	18.47	20.66	25.63
Price / Sales	120.06	294.84	542.63	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	2.35	6.93	9.93	6.97
Net Income	-$51.04M	$24.11M	$3.55B	$333.62M
7 Day Performance	-4.41%	5.89%	1.70%	1.09%
1 Month Performance	21.42%	-0.91%	0.49%	3.08%
1 Year Performance	122.66%	74.58%	39.41%	35.68%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	3.4854 of 5 stars	$7.37 -3.0%	$28.63 +288.4%	+137.7%	$247.65M	$2M	N/A	8	Earnings Report Analyst Revision
PHAT Phathom Pharmaceuticals	2.9129 of 5 stars	$12.32 -4.3%	$25.00 +102.9%	+301.5%	$982.88M	$175.11M	N/A	110	Positive News
MRVI Maravai LifeSciences	2.988 of 5 stars	$3.80 +0.1%	$5.38 +41.6%	+116.7%	$975.58M	$185.74M	N/A	610	Analyst Downgrade Options Volume
ORIC Oric Pharmaceuticals	2.1582 of 5 stars	$9.28 -3.7%	$19.90 +114.6%	+71.6%	$959.11M	N/A	N/A	80
SDGR Schrodinger	3.3714 of 5 stars	$12.80 -0.8%	$20.50 +60.2%	-47.2%	$944.96M	$255.87M	N/A	790	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. PHAT, MRVI, ORIC, SDGR, and XNCR

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Maravai LifeSciences?

Summary

How does Sagimet Biosciences compare to Oric Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Schrodinger?

Summary

How does Sagimet Biosciences compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. PHAT, MRVI, ORIC, SDGR, and XNCR

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Does the media prefer SGMT or PHAT?

Do analysts prefer SGMT or PHAT?

Is SGMT or PHAT more profitable?

Do insiders & institutionals hold more shares of SGMT or PHAT?

Which has stronger earnings and valuation, SGMT or PHAT?

Which has more volatility & risk, SGMT or PHAT?

Summary

How does Sagimet Biosciences compare to Maravai LifeSciences?

Does the media prefer SGMT or MRVI?

Which has more volatility & risk, SGMT or MRVI?

Is SGMT or MRVI more profitable?

Do analysts prefer SGMT or MRVI?

Which has stronger earnings and valuation, SGMT or MRVI?

Do insiders & institutionals hold more shares of SGMT or MRVI?

Summary

How does Sagimet Biosciences compare to Oric Pharmaceuticals?

Does the media favor ORIC or SGMT?

Which has better valuation & earnings, ORIC or SGMT?

Do insiders and institutionals believe in ORIC or SGMT?

Is ORIC or SGMT more profitable?

Which has more risk & volatility, ORIC or SGMT?

Do analysts recommend ORIC or SGMT?

Summary

How does Sagimet Biosciences compare to Schrodinger?

Is SGMT or SDGR more profitable?

Which has more risk and volatility, SGMT or SDGR?

Do institutionals & insiders believe in SGMT or SDGR?

Which has stronger earnings and valuation, SGMT or SDGR?

Do analysts recommend SGMT or SDGR?

Does the media prefer SGMT or SDGR?

Summary

How does Sagimet Biosciences compare to Xencor?

Does the media prefer SGMT or XNCR?

Do analysts recommend SGMT or XNCR?

Is SGMT or XNCR more profitable?

Which has more risk and volatility, SGMT or XNCR?

Which has stronger earnings and valuation, SGMT or XNCR?

Do institutionals & insiders believe in SGMT or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools